1. Home
  2. PEB vs RAPP Comparison

PEB vs RAPP Comparison

Compare PEB & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pebblebrook Hotel Trust of Beneficial Interest

PEB

Pebblebrook Hotel Trust of Beneficial Interest

HOLD

Current Price

$19.21

Market Cap

1.7B

Sector

Real Estate

ML Signal

HOLD

RAPP

Rapport Therapeutics Inc.

HOLD

Current Price

$41.08

Market Cap

1.8B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
PEB
RAPP
Founded
2009
2022
Country
United States
United States
Employees
52
N/A
Industry
Real Estate Investment Trusts
Sector
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.8B
IPO Year
N/A
2024

Fundamental Metrics

Financial Performance
Metric
PEB
RAPP
Price
$19.21
$41.08
Analyst Decision
Hold
Strong Buy
Analyst Count
11
6
Target Price
$13.30
$48.50
AVG Volume (30 Days)
2.3M
433.0K
Earning Date
04-28-2026
05-08-2026
Dividend Yield
0.28%
N/A
EPS Growth
N/A
24.34
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$2.25
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.30
$13.64
52 Week High
$19.93
$44.28

Technical Indicators

Market Signals
Indicator
PEB
RAPP
Relative Strength Index (RSI) 58.40 52.52
Support Level $17.64 $38.55
Resistance Level $19.68 $43.70
Average True Range (ATR) 0.51 2.88
MACD -0.03 -0.09
Stochastic Oscillator 67.47 41.38

Price Performance

Historical Comparison
PEB
RAPP

About PEB Pebblebrook Hotel Trust of Beneficial Interest

Pebblebrook Hotel Trust currently owns upper upscale and luxury hotels with 11,052 rooms across 44 hotels in the United States. Pebblebrook acquired LaSalle Hotel Properties, which owned 10,451 rooms across 41 US hotels, in November 2018, though management has sold many of those hotels over the past few years. Pebblebrook's portfolio consists mostly of independent hotels with no brand affiliations, though the combined company does own and operate some hotels under Marriott, Starwood, InterContinental, Hilton, and Hyatt brands.

About RAPP Rapport Therapeutics Inc.

Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.

Share on Social Networks: